Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 52 Publications

12 Customer Reviews

  • (G) A375 parental and BRAFi-resistant ex vivo clones were treated with a panel of HDACi (1 μM vorinostat, 0.5 μM belinostat, and 6 nM panobinostat) in single treatment or in combination with 1 μM vemurafenib in a long-term colony formation assay.

    Cell, 2018, 173(6):1413-1425. Panobinostat (LBH589) purchased from Selleck.

    LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

  • Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

  • HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

    U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy2b4U6OC1zMDFOwG0> NFjhZ2wxNTRiZB?= MorWbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmLBNlY4ODJ5OES=
HepG2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:wMVExKM7:TR?= MWSwMVQh\A>? NVLOdoNJcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWqyOlcxOjd6NB?=
HT29 MmjBSpVv[3Srb36gRZN{[Xl? MlvOOVDDqG6P NWHqSoI3OjRvN{KgbC=> M3jWcYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=> Ml;rNlY4ODJ5OES=
HepG2 MUDGeY5kfGmxbjDBd5NigQ>? NUfsNpA2PTEEoH7N M{K5TFI1NTd{IHi= MUXpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G|cHHz[UA{KGGodHXyJFI1yqCqwrC= M4fwV|I3PzB{N{i0
HCC827 M2XjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYq1M|cvPS9zMDDuUS=> MWe3NuKhcA>? NYKzNVVrTE2VTx?= MnLj[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? NHPufFUzPjZ5NUS4OC=>
A549  MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuxNE8yPS9{MDDuUS=> M3HYVlczyqCq MlS3SG1UVw>? M4rFO4VvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk NGryWY0zPjZ5NUS4OC=>
NCI-H460  MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3kfHJjOTBxMkCvN|Ahdk1? NWj6XJFOPzMEoHi= NYj4R4xwTE2VTx?= MYTlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? M3rmT|I3Pjd3NEi0
J89GFP MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfoSG1UV8Li M2PMN2VEPTB;NEmuPFUhyrFiMUKuOlUhdk1? NWD4OIJGOjZ3NkO1Olg>
THP89GFP NHf1[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDEUXNQyqB? M2\SbWVEPTB;MUmuN|QhyrFiNj60N{BvVQ>? MnPUNlY2PjN3Nki=
SK-NEP-1 MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjOUXIxNjBz4pETNVAvOCEQvF2= MmLyNlQhcA>? NW\DVmpOTE2VT9Mg M4\aSGlEPTB;N{[uN|Qhdk1? NFTRUpIzPjF5NkKxPS=>
G401 Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG0S|gxOC5yMfMAl|ExNjBizszN M{PWdVI1KGh? M4PnXWROW00EoB?= NFLjcppKSzVyPUG0N{4xOiCwTR?= M4fMSFI3OTd4MkG5
SK-NEP-1 NXLqdZM2S2WubDDWbYFjcWyrdImgRZN{[Xl? MmrhOVAhdk1? NHTvb4Uy6oDVNDDk MmfLSG1UV8Li MljYdoVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz MojsNlYyPzZ{MUm=
G401 M2T5eWNmdGxiVnnhZoltcXS7IFHzd4F6 NGH6WYY2OCCwTR?= NX\1fWNPOeLCk{Sg[C=> M3HCT2ROW00EoB?= MWTy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MVKyOlE4PjJzOR?=
SK-NEP-1 NG\vPW1CeG:ydH;zbZMhSXO|YYm= NGW0NJU2OC9zMECgcm0> MonmNlQhcA>? NEWxWGhFVVORwrC= NFfzUZNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1r4elI3OTd4MkG5
G401 Mmj2RZBweHSxc3nzJGF{e2G7 NWDY[3puPTBxMUCwJI5O NFzwOpUzPCCq MYDEUXNQyqB? NIPvT4lqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXmyOlE4PjJzOR?=
SK-NEP-1 NFLyXJBHfW6ldHnvckBCe3OjeR?= NVHi[nJLPTBxMUCwJI5O NXftUotiOjRiaB?= NW\lbo5XTE2VT9Mg MVfzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v MVuyOlE4PjJzOR?=
G401 MWjGeY5kfGmxbjDBd5NigQ>? MXO1NE8yODBibl2= MlfjNlQhcA>? MoXqSG1UV8Li M4XEPJNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? NGS1OmMzPjF5NkKxPS=>
SK-NEP-1 NV7lbW45TnWwY4Tpc44hSXO|YYm= NUnvSHdOPTBxMUCwJI5O MVmyOEBp NFfOWnNFVVORwrC= NXW5VoJXcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? MV[yOlE4PjJzOR?=
G401 MnrWSpVv[3Srb36gRZN{[Xl? NEPaRWU2OC9zMECgcm0> MUWyOEBp NHjtZYlFVVORwrC= M4nBO4lv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh MV[yOlE4PjJzOR?=
RPMI 8226 NWXFZ4J6S2WubDDTeZJ3cX[jbDDBd5NigQ>? NWS5OXROOi92L{[gcm0> MkLFOFjjiImq MkT4bY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? MnLZNlYxODB{OUK=
OPM2 MWLD[YxtKFO3co\peoFtKEG|c3H5 NFfFdpgzNzRxNjDuUS=> NYjrS|lHPDkkgJno Mo\rbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? M{LiS|I3ODByMkmy
U266 NHzie2dE\WyuIGP1dpZqfmGuIFHzd4F6 MXSyM|QwPiCwTR?= MXm0PQKBkWh? MlP6bY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? NEDNZ4EzPjByMEK5Ni=>
H929 NWfoW3Q6S2WubDDTeZJ3cX[jbDDBd5NigQ>? M4HCbVIwPC94IH7N MXK0PQKBkWh? MYjpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp NHPLUWkzPjByMEK5Ni=>
RPMI 8226  NXzCN3R5SXCxcITvd4l{KEG|c3H5 MU[05qCKdk1? NFXFTZczPC92ODDo M1\tVolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MkLzNlYxODB{OUK=
HCC827 M1vWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOxNEBvVQ>? MWC0PEBp NIjiOoFFVVOR MY\lcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? MnXYNlU6PDR4MUe=
NCI-H23 NYnNe|NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLZRZdtOTBibl2= MWS0PEBp NFTRcWNFVVOR NGX0e4dmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= NGryVnQzPTl2NE[xOy=>
AML3 MUnGeY5kfGmxbjDBd5NigQ>? NWHhS25iOC1zIN88US=> M2POcFI1yqCq MmCwbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFPoVGYzPTZzMkm0NS=>
ML-1 M2rqVmZ2dmO2aX;uJGF{e2G7 MWewMVEh|ryP M2LlWFI1yqCq MYXpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXjlW4FNOjV4MUK5OFE>
RPMI-8226vr10  NF3lT3hHfW6ldHnvckBCe3OjeR?= NWPpXVl[OC1zIN88US=> M4m2dVI1yqCq Mlz4bY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlnmNlU3OTJ7NEG=
ML-1 NGP3R|lHfW6ldHnvckBCe3OjeR?= MlrMNUDPxE1? M{X6c|I1yqCq M1PVUolv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhPC2ob3zk M{G2RVI2PjF{OUSx
RPMI-8226vr10  M2jlU2Z2dmO2aX;uJGF{e2G7 NGLTPHkyKM7:TR?= MXWyOOKhcA>? MVPpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFIvPS2ob3zk NVLlZVBSOjV4MUK5OFE>
SK-N-BE (2) NXz5RnVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Prc|I16oDLaB?= NIPmOG9KSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= MnK2NlU{ODh7MU[=
SK-N-BE (2), PAN  MK NGj1[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfiNlTjiImq M1fWUmlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= M4\DSFI2OzB6OUG2
SK-N-BE (2), MK  PAN NETDSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X6V|I16oDLaB?= NVPwfVRrUUN3ME2zPFIvOOLCidMx5qCKPDNwMjDuUS=> M1fjO|I2OzB6OUG2
SK-N-AS NVLhdW55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTkdHRmOjUkgJno MorYTWM2OD1|Nz6x5qCKyrIkgJmyMlQhdk1? M{TYblI2OzB6OUG2
SK-N-DZ NUjnXnRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm3fnhHOjUkgJno MlrQTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1? NFnkT5YzPTNyOEmxOi=>
Caki-1 NInqO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPReosyOC9{NT:1NEBvVQ>? MXS0PEBp MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? NI\RWIQzPTJ5OUG5NS=>
ACHN M{fqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPOZoU2OTBxMkWvOVAhdk1? NIfVTVQ1QCCq MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? Mmf4NlUzPzlzOUG=
769-P M3L2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnqPW4yOC9{NT:1NEBvVQ>? NYSxTXhNPDhiaB?= MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? Mn\SNlUzPzlzOUG=
786-O  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPrU3FOOTBxMkWvOVAhdk1? MWW0PEBp Mmf4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MkL3NlUzPzlzOUG=
Caki-1 NHn0UVNCeG:ydH;zbZMhSXO|YYm= M2eyN|UxKG6P M1jw[|Q5KGh? Ml\3bY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? NVf2[5k3OjV{N{mxPVE>
ACHN MYjBdI9xfG:|aYOgRZN{[Xl? MX:1NEBvVQ>? M4fZRlQ5KGh? M2jFOYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ NX7KR2pSOjV{N{mxPVE>
769-P NVX2dVdzSXCxcITvd4l{KEG|c3H5 MnmzOVAhdk1? NIfOZ2g1QCCq NV7nbWUzcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= NI\YNm0zPTJ5OUG5NS=>
786-O  M2L5d2Fxd3C2b4Ppd{BCe3OjeR?= NI\6cnU2OCCwTR?= MXi0PEBp M1\KSIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ MXKyOVI4QTF7MR?=
Caki-1 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDrNlUwPTBibl2= Mnr0OFghcA>? NGPJTlhFVVOR MXrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MVyyOVE4PjN3NB?=
ACHN MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSyOU82OCCwTR?= M2HWZVQ5KGh? NWPmT5RmTE2VTx?= Ml74bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= M{TkTlI2OTd4M{W0
769-P NUK0XGRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWiyOU82OCCwTR?= NILlO4s1QCCq NX7EcW51TE2VTx?= MojmbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= NF;BfnEzPTF5NkO1OC=>
Caki-1 MoPSR49td267IF\vdo1ifGmxbjDBd5NigQ>? MWq1NEBvVQ>? MkHXO{0yPCCm M{iwNGROW09? NXvrN3pRe3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? NEPvSGYzPTF5NkO1OC=>
ACHN MmfyR49td267IF\vdo1ifGmxbjDBd5NigQ>? MkPpOVAhdk1? NEC5Zos4NTF2IHS= MYLEUXNQ Mm\xd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> NGLFXmozPTF5NkO1OC=>
769-P M1LKTmNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? M1nlOlUxKG6P M1XWOFcuOTRiZB?= NEjR[llFVVOR M{fmN5N2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh NF65N2YzPTF5NkO1OC=>
Caki-1 M1;sdWFxd3C2b4Ppd{BCe3OjeR?= Ml\EOVAhdk1? NUP0c4lHPDhiaB?= MnzaSG1UVw>? NHvqPXJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M1nmU|I2OTd4M{W0
ACHN M4PvbGFxd3C2b4Ppd{BCe3OjeR?= MYe1NEBvVQ>? MlvQOFghcA>? MYLEUXNQ M{XXW4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MmXHNlUyPzZ|NUS=
769-P NYHQTlNYSXCxcITvd4l{KEG|c3H5 M1vNelUxKG6P NUXG[5RnPDhiaB?= M3Huc2ROW09? NHvVU4lqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NGmwUm4zPTF5NkO1OC=>
MDA-MB-231 MY\Nc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> MkDoNVDDqG6P NIfnNFI{yqCm MUXEUXNQ NIX0c5BidHSncoOgZ4VtdCCvb4LwbI9td2e7wrC= NXzpcpQ6OjR6MUC0PVc>
BT-549 NELW[nNOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? M1\NfFExyqCwTR?= M1\mcVPDqGR? M4rFWWROW09? NVXvOGhb[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg Ml3CNlQ5OTB2OUe=
MCF-7  M1O0fm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? Mo\mNVDDqG6P MVOzxsBl NFj6fpNFVVOR M3\GSYFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= NF7hUpQzPDhzMES5Oy=>
MCF-7 MVfGeY5kfGmxbjDBd5NigQ>? MmTKOU02OCCwTR?= MYWyOEBp M1XiZ2ROW09? M{\zdpJm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> M{ewc|I1OzZ4NEC3
CTS MUfBdI9xfG:|aYOgRZN{[Xl? NXH2PJB3OOLCk{SwJI5OyqB? MYG0PEBp NUTufIw6cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{fUWlI1OjR2NEK5
OCI-AML3  M4\j[WFxd3C2b4Ppd{BCe3OjeR?= M2HXSFDjiJN2MDDuUeKh M2LnSlQ5KGh? MoTSbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Ml7PNlQzPDR2Mkm=
U937 M1mybGFxd3C2b4Ppd{BCe3OjeR?= NHLRR5Ix6oDVNECgcm3DqA>? Mn\KOFghcA>? MYPpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUXBTZV2OjR{NES0Nlk>
PC3 NGnsSFRCeG:ydH;zbZMhSXO|YYm= MlP3NE0yODBibl2= MXSyOE81QCCq NIXPNotqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3n2WlI1OTZ|MkOw
PC3-AR MXjBdI9xfG:|aYOgRZN{[Xl? M1O0e|AuOTByIH7N NGrRZY0zPC92ODDo MXzpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYWyOFE3OzJ|MB?=
PC3 NHfPPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvwS2RTOC1zMECgcm0> MoXPNlQwPDhiaB?= NH3VfYVqdmS3Y3XzJIFk[3WvdXzheIlwdiCxZjDzeYJIOSCyb4D1cIF1cW:w Mn:5NlQyPjN{M{C=
PC3-AR M4jqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKwe|NGOC1zMECgcm0> M4n1RVI1NzR6IHi= MVHpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJJRp\SCJMl2gdIhie2V? NULBVYUyOjRzNkOyN|A>
PC3 MUDGeY5kfGmxbjDBd5NigQ>? Mni3NE0yODBibl2= M1m1XVI1KGh? MVnzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= MXGyOFE3OzJ|MB?=
PC3-AR NV\ETok4TnWwY4Tpc44hSXO|YYm= NYrEeHBiOC1zMECgcm0> M{LURlI1KGh? MmTpd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= MYeyOFE3OzJ|MB?=
OS-RC-2 Ml;BR4VtdCCYaXHibYxqfHliQYPzZZk> MVOwMVExODBibl2= MmLONlQwPDhxN{KgbC=> MlnQSG1UVw>? MXrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUPHdo1SOjRzNES3N|c>
OS-RC-2 NXTwUpM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q5ZVUxKG6P NYrmeW1mPDhiaB?= Mnj4SG1UVw>? MmPNbY5lfWOnczDHNk9OKGG{cnXzeC=> NFW2TI4zPDF2NEezOy=>
OS-RC-2 NHP4UWFCeG:ydH;zbZMhSXO|YYm= NILDWG82OCCwTR?= NF21UoU1QCCq NGizPIFFVVOR MYDpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MWqyOFE1PDd|Nx?=
SK-N-AS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH6yXocx6oDVOECgcm0> MXu0PEBp M4XScGlEPTB;MkeuOEBvVQ>? NFWxOZgzPDB7OEe5PS=>
SK-N-DZ MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXFUpBLOOLCk{iwJI5O M3;2[lQ5KGh? NHHo[lFKSzVyPUKxMlkhdk1? MnjRNlQxQTh5OUm=
SK-N-SH NELLWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjEd2tlOOLCk{iwJI5O MoKwOFghcA>? NF7XRnBKSzVyPUeyMlMhdk1? MVOyOFA6QDd7OR?=
SK-N-BE MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPjcZYx6oDVOECgcm0> MVi0PEBp M372VWlEPTB;N{WuOEBvVQ>? MUiyOFA6QDd7OR?=
SK-N-AS MomwRZBweHSxc3nzJGF{e2G7 NUDrWIhxOOLCk{iwJI5O Mk\yOFghcA>? MkLJdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MnXPNlQxQTh5OUm=
SK-N-DZ NFTvSHFCeG:ydH;zbZMhSXO|YYm= NHzIUJYx6oDVOECgcm0> NWnqRXEyPDhiaB?= Mny4dI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MWWyOFA6QDd7OR?=
SK-N-SH MoLxRZBweHSxc3nzJGF{e2G7 NGTwWVYx6oDVNECgcm0> MmnJOFghcA>? MUHwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= NFfGPW8zPDB7OEe5PS=>
SK-N-BE NInVWZdCeG:ydH;zbZMhSXO|YYm= NEnJeZYx6oDVNECgcm0> M2HDV|Q5KGh? M3e5SJBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> NX[5UGtoOjRyOUi3PVk>
SK-N-AS M2TiemZ2dmO2aX;uJGF{e2G7 NXXucXNHOOLCk{iwJI5O NGPN[m81QCCq MWnpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ Mn\RNlQxQTh5OUm=
SK-N-DZ Mlv1SpVv[3Srb36gRZN{[Xl? MmHONQKBmzhyIH7N M1jLOlQ5KGh? MUDpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ NHjhS3QzPDB7OEe5PS=>
SK-N-SH NID6S3JHfW6ldHnvckBCe3OjeR?= NEDNZXkx6oDVNECgcm0> NYfQWGd3PDhiaB?= MoDNbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MWiyOFA6QDd7OR?=
SK-N-BE NEXjeJVHfW6ldHnvckBCe3OjeR?= NHLuWmQx6oDVNECgcm0> MUG0PEBp NFPBWlBqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR NYO4e4lyOjRyOUi3PVk>
HCC-LM3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2xMVExODBibl2= MmT6NlQwPDhxN{KgbC=> M4O4XGROW09? NInMS21qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NE\lU4ozPDB7M{m1Oi=>
HepG2 NEXsfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojVNU0yODByIH7N M4ThW|I1NzR6L{eyJIg> NIjPdYFFVVOR NGXLW4hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MXKyOFA6Ozl3Nh?=
SMMC-7721 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj0[IpjOS1zMECwJI5O MUeyOE81QC95MjDo NUXjXFJFTE2VTx?= Mnj0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmS4NlQxQTN7NU[=
HCC-LM3 M4\qTmFxd3C2b4Ppd{BCe3OjeR?= MmrLOVAhdk1? MU[0PEBp M3vpcWROW09? M2[4Wolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 MYeyOFA6Ozl3Nh?=
HepG2 NVzjOYZOSXCxcITvd4l{KEG|c3H5 NHrKWGg2OCCwTR?= NV7CepNzPDhiaB?= MYnEUXNQ M3SxXIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 M37p[VI1ODl|OUW2
SMMC-7721 M2XWb2Fxd3C2b4Ppd{BCe3OjeR?= NFjm[lc2OCCwTR?= NFnyT|I1QCCq NGjqeZFFVVOR M3zQ[4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 MnLmNlQxQTN7NU[=
HCC-LM3 NHvYR3JHfW6ldHnvckBCe3OjeR?= M2rTSVUxNzFyMDDuUS=> MX[yOEBp M2ri[GROW09? Mn;R[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= Mk\hNlQxQTN7NU[=
HepG2 NHXjfHJHfW6ldHnvckBCe3OjeR?= M4TNdVUxNzFyMDDuUS=> NEW1T2MzPCCq MUjEUXNQ Mm\N[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= MnrjNlQxQTN7NU[=
SMMC-7721 M2\5Z2Z2dmO2aX;uJGF{e2G7 MkHMOVAwOTByIH7N NIHpcmUzPCCq NYrqcpI3TE2VTx?= MnTV[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= MkSxNlQxQTN7NU[=
HCC-LM3 NHu3SVhHfW6ldHnvckBCe3OjeR?= MX21NE8yODBibl2= NILld2kzPCCq NUS2PVZoTE2VTx?= MULkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v NIDRfnkzPDB7M{m1Oi=>
HepG2 MkK2SpVv[3Srb36gRZN{[Xl? Mn60OVAwOTByIH7N MnHTNlQhcA>? NUD0OXNWTE2VTx?= NYrUW3Zt\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NFvGd24zPDB7M{m1Oi=>
SMMC-7721 NGjNNW1HfW6ldHnvckBCe3OjeR?= Mo\oOVAwOTByIH7N NELkW2IzPCCq M1LR[GROW09? MoGy[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? M1fuRVI1ODl|OUW2
FaDu M{PCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm0W|IyODEkgJXuUS=> MlzCPE8yOC9zMjDo M2PjbYRqe3CuYYnl[EBiKHOrZ37p[olk[W62IHHu[EBxem:ub37n[YQhTzJxTTDhdpJme3RiYYSgPEBidmRiMUNihKVpKHCxc4SgdoVt\WG|ZR?= NHy0TmszPDB{NkS4Ni=>
FaDu NG\IUoJHfW6ldHnvckBCe3OjeR?= NFLUOG0yODEkgJXuUS=> Mn7vNk81NzhxMUKgbC=> M1;S[olv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w NYXTNYF{OjRyMk[0PFI>
PC-3  M2SwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3hSWVCOC1zMDFOwG0> NXfnRZBEOjRxNEivO|IhcA>? MkjybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MV6yN|k6OTJzNh?=
LNCaP NFrqcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7KcHNHOC13IN88US=> MlPJNlQwPDhxN{KgbC=> NUXWRppNcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYeyN|k6OTJzNh?=
RWPE-1  MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSwMVIxKM7:TR?= M1PYVlI1NzR6L{eyJIg> NFWwXIFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3yzbVI{QTlzMkG2
Capan-1 NHnJPXFHfW6ldHnvckBCe3OjeR?= MWCyOU82OC9zMECgcm0> MWe4M|I1NzR6IHi= M1HiV2ROW09? M3u1cYRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= MU[yN|kzOjh6Nh?=
L3.6pl NX3SRoU6TnWwY4Tpc44hSXO|YYm= MVqyOU82OC9zMECgcm0> MW[4M|I1NzR6IHi= NVvZWItzTE2VTx?= MVnkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p MVqyN|kzOjh6Nh?=
CFPAC-1  MV\GeY5kfGmxbjDBd5NigQ>? NYLzVpB[OjVxNUCvNVAxKG6P MWS4M|I1NzR6IHi= M{W1VmROW09? Mlyz[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= MVSyN|kzOjh6Nh?=
Capan-1 MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\J[5FuOjVxNUCvNVAxKG6P NHLKVHI1QCCq NUDheHYxTE2VTx?= NYLldFNmemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1;JblI{QTJ{OEi2
L3.6pl MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjlXFUzPS93MD:xNFAhdk1? NX\WdWNsPDhiaB?= Moe3SG1UVw>? M{PoepJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYnLdWFOOjN7MkK4PFY>
CFPAC-1  NIq0bYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLlNlUwPTBxMUCwJI5O MnHLOFghcA>? MYXEUXNQ M1jkRpJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmT4NlM6OjJ6OE[=
Capan-1 NEjRV45CeG:ydH;zbZMhSXO|YYm= MmfFNlUwPTBxMUCwJI5O NFnWUlI1QCCq NUnEdI1FTE2VTx?= M3n1NIlv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mn;CNlM6OjJ6OE[=
L3.6pl MnPvRZBweHSxc3nzJGF{e2G7 MlzpNlUwPTBxMUCwJI5O M1zjblQ5KGh? NX3PRmJETE2VTx?= MXnpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4ft[VI{QTJ{OEi2
CFPAC-1  MWfBdI9xfG:|aYOgRZN{[Xl? NXvEdWhCOjVxNUCvNVAxKG6P MoDoOFghcA>? Mn72SG1UVw>? NXvDcmRFcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NF3HOHIzOzl{Mki4Oi=>
HN22 NXPnO|cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6wMVIxKG6P NGfDNpIzPC92ODDo M4rF[2ROW09? M1KyZolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NH\BWZYzOzh5N{KzOS=>
HSC4  MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKwMVIxKG6P MlLPNlQwPDhiaB?= M{iwTGROW09? NX71blZOcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? MVmyN|g4PzJ|NR?=
HN22 MV7BdI9xfG:|aYOgRZN{[Xl? MkHyNE0zOCCwTR?= MY[0PEBp NGLkOnFFVVOR M{DDOolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NIL6eYgzOzh5N{KzOS=>
HSC4  M3HEcmFxd3C2b4Ppd{BCe3OjeR?= MkjFNE0zOCCwTR?= MXS0PEBp MlT3SG1UVw>? NWLy[oNFcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MkPUNlM5Pzd{M{W=
HN22 NF33Tm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrGNE0zOCCwTR?= NVjiVZd7PDhiaB?= Mn3lSG1UVw>? MUXpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= Mn\UNlM5Pzd{M{W=
HSC4  M2HsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHixT2oxNTJyIH7N MYG0PEBp NInXNllFVVOR MknkbY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dNMg MWGyN|g4PzJ|NR?=
HN22 NIOyR|NHfW6ldHnvckBCe3OjeR?= NIfY[pgxNTJyIH7N NHXYOo81QCCq M1fBUGROW09? MWDzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= NILoZ|EzOzh5N{KzOS=>
HSC4  M2[yNGZ2dmO2aX;uJGF{e2G7 NI[xN4YxNTJyIH7N MYK0PEBp MULEUXNQ MX7zeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= MnH2NlM5Pzd{M{W=
Cal62 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjwWoJMUUN3ME2zN{DDuSB2IH7N MnPDNlM5OjRyNkS=
Hth7 M3:4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\YcmlEPTB;MUWgxtEhOiCwTR?= NV7pV|N[OjN6MkSwOlQ>
Hth83 NXHoUWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTN2INMxJFUhdk1? MlfYNlM5OjRyNkS=
C643 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXXelJKSzVyPUexJOKyKDFyIH7N MXeyN|gzPDB4NB?=
SW1736 M2X3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH2UJRKSzVyPUO1JOKyKDhibl2= NITOZYczOzh{NEC2OC=>
T241 Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTZ3INMxJFchdk1? NX3mSmtrOjN6MkSwOlQ>
T351 NV;5b4hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\GRodKSzVyPUWwJOKyKDFyIH7N NYfFdWNUOjN6MkSwOlQ>
BHP2-7 M{fqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HOcGlEPTB;M{egxtEhPiCwTR?= NFzoNpozOzh{NEC2OC=>
T238 M1q4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGWwZm9KSzVyPUGsOVAxKMLzIEKwNEBvVQ>? NFK4eHkzOzh{NEC2OC=>
HCT8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\GUZc4OiCq NX;LZWNQTE2VTx?= NY\1VJV3UUN3ME2xNk466oDLwsJihKkyNjlibl2= MoTYNlMzQTl|OEi=
H630 MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUG3NkBp NVLRS4ZGTE2VTx?= M2\ON2lEPTB;MUKuOQKBkcLz4pEJN{4yKG6P MXqyN|I6QTN6OB?=
cH630 5-FU-res M3XIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnYR3hMPzJiaB?= MWLEUXNQ NEf4d4xKSzVyPUG1MlXjiIoEsfMAjVEvOiCwTR?= NYLzOJY6OjN{OUmzPFg>
HCT116 NYPGTXlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX23NkBp NVXrcGkzTE2VTx?= NFzMVlRKSzVyPUGwMlfjiIoEsfMAjVIvOiCwTR?= MnLqNlMzQTl|OEi=
HCT116 p53−/− MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nYb|czKGh? M17scmROW09? NWLZdYVoUUN3ME24MlbjiIoEsfMAjVEvPyCwTR?= MlvZNlMzQTl|OEi=
dHCT116 p21−/− MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHYeWM4OiCq M{C2VmROW09? MmO4TWM2OD13LkpihKnDueLCiUGuN{BvVQ>? MVOyN|I6QTN6OB?=
HT29 M{Kycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWG3NkBp M4fHd2ROW09? M1PqUWlEPTB;MU[uN-KBkcLz4pEJNk4{KG6P NUjtNYhiOjN{OUmzPFg>
LoVo NYnvUIRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7nOXRZPzJiaB?= NXHsZVkyTE2VTx?= NEDjc|JKSzVyPUWuNgKBkcLz4pEJNE43KG6P Mn6yNlMzQTl|OEi=
RKO NHPKe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi5UIY4OiCq MYjEUXNQ NXPwVlJOUUN3ME23MlnjiIoEsfMAjVIvOiCwTR?= NGPDcGYzOzJ7OUO4PC=>
SW480 M4PlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LwXFczKGh? MnLHSG1UVw>? NGDG[FFKSzVyPUG3MlXjiIoEsfMAjVAvQCCwTR?= NVSyWYVHOjN{OUmzPFg>
eSW620 MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWS3NkBp MXnEUXNQ NVnHeHJ4UUN3ME25MlHjiIoEsfMAjVIvOSCwTR?= NX;qZY9KOjN{OUmzPFg>

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Cancer Center September 2018 Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2
NCT03256045 Recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma University of Washington|National Cancer Institute (NCI) February 8 2018 Phase 2
NCT02961816 Withdrawn Lymphoma M.D. Anderson Cancer Center June 2017 Phase 2
NCT02802163 Withdrawn Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen June 2017 Phase 1|Phase 2
NCT02756663 Withdrawn Multiple Myeloma Novartis Pharmaceuticals|Novartis December 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID